A Phase 1, Randomized, Double-Blind Study of the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine With an Adjuvant Administered in Adults 50 Through 64 Years of Age
Latest Information Update: 01 Aug 2024
At a glance
- Drugs PF-07872411 (Primary) ; PCV 20
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 29 Jul 2024 Status changed from active, no longer recruiting to completed.
- 11 Feb 2024 Planned End Date changed from 12 Nov 2024 to 15 Jul 2024.
- 11 Feb 2024 Planned primary completion date changed from 12 Nov 2024 to 15 Jul 2024.